Pfizer Inc. (PFE) Stock Rating Reaffirmed by BMO Capital Markets

Pfizer Inc. (NYSE:PFE)‘s stock had its “hold” rating reissued by equities research analysts at BMO Capital Markets in a research report issued to clients and investors on Tuesday. They presently have a $33.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential downside of 4.01% from the company’s previous close.

A number of other brokerages have also issued reports on PFE. Barclays PLC set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, March 16th. Vetr lowered shares of Pfizer from a “hold” rating to a “sell” rating and set a $33.45 target price on the stock. in a research report on Thursday, March 2nd. Sanford C. Bernstein set a $35.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, March 13th. Credit Suisse Group AG set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, March 13th. Finally, Jefferies Group LLC set a $34.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, March 9th. Thirteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.32.

Analyst Recommendations for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) opened at 34.38 on Tuesday. The company has a 50 day moving average of $33.34 and a 200 day moving average of $32.84. Pfizer has a 1-year low of $29.17 and a 1-year high of $37.39. The firm has a market capitalization of $204.63 billion, a PE ratio of 29.31 and a beta of 0.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by $0.03. The business had revenue of $13.60 billion for the quarter, compared to analysts’ expectations of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The business’s revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.53 earnings per share. Analysts forecast that Pfizer will post $2.55 EPS for the current year.

var userip;Your IP Address: document.write(userip);

In other Pfizer news, insider Rady A. Johnson sold 4,500 shares of the firm’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $34.19, for a total value of $153,855.00. Following the completion of the sale, the insider now owns 54,963 shares of the company’s stock, valued at $1,879,184.97. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mikael Dolsten sold 30,970 shares of the firm’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $34.51, for a total value of $1,068,774.70. Following the completion of the sale, the insider now directly owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The disclosure for this sale can be found here. In the last three months, insiders sold 71,470 shares of company stock valued at $2,449,150. 0.07% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Fusion Family Wealth LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $109,000. First National Bank Sioux Falls increased its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,750 shares during the period. Cornerstone Advisors Inc. increased its stake in Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 541 shares during the period. Gierl Augustine Investment Management Inc increased its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares during the period. Finally, Stanford Investment Group Inc. increased its stake in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares during the period. 69.53% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Oil Prices Drop to Low of Three Months on Rig Count
Oil Prices Drop to Low of Three Months on Rig Count
Shares of Staples Fall After Earnings Come Up Short
Shares of Staples Fall After Earnings Come Up Short
Trump Tweet Sends Pharmaceutical Stocks Tumbling
Trump Tweet Sends Pharmaceutical Stocks Tumbling


Leave a Reply

© 2006-2017 Ticker Report. Google+.